AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: trial

newssourceFORcompanyinformationcontent1releasesmarket

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Ambient Carbon Destroys 90% of Dairy Barn Methane in Field Trial

COPENHAGEN, Denmark, Aug. 12, 2025 /PRNewswire/ -- A field trial in Denmark shows Ambient Carbon's Methane Eradication Photochemical System (MEPS) eliminated up to 90%...

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial

During Sleep Health Week (11-15 August 2025), Australians living with insomnia are reminded that a new treatment is on the horizon – with clinical...

Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...

Anteris Announces Results for the Second Quarter of 2025

Anteris Announces Results for the Second Quarter of 2025

Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth...

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT – TORONTO and DALLAS, Aug. 11, 2025 /PRNewswire/ - Perimeter Medical Imaging AI,...

Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth...

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT – TORONTO and DALLAS, Aug. 11, 2025 /CNW/ - Perimeter Medical Imaging AI,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers